In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.more
Introducing cancer immunotherapy
The cancer immunity cycle
A new framework is redefining how we implement personalised cancer immunotherapy research around the world.more
Collaboration in research
Cancer remains one of the leading causes of death worldwide, but world-class research provides hope.more
About bladder cancer
Bladder cancer is one of the top ten most common cancers in the world.more
About lung cancer
Lung cancer has been the most common cancer in the world for several decades, accounting for 1 in 5 of all cancer deaths.more
About renal cell carcinoma
Renal cell carcinoma is the most common form of kidney cancer, accounting for approximately 90% of casesmore
Biomarkers in cancer
Biomarkers continue to play a critical role in the development of personalised healthcare, particularly in cancer.more
A pocket guide to interpreting data
Obtain simple definitions of clinical terms with our pocket guide to interpreting data.
Linking T-cells and cancer cells
When the body’s own immune system fails, T-cell bispecific antibodies help T-cells spring back into action and attack cancer cells.
CEO on cancer immunotherapy
Roche CEO Severin Schwan talks about our commitment and leadership in this exciting field.
The PD-L1 pathway
The role of the immune system is to protect the body from foreign invaders. PD-L1 can help tumour cells evade the immune surveillance.